Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. (TPTX): 4 pipeline candidates · ~23 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
22.7 months
0% dilution
Lead: Phase 1/Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Turning Point Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$290.1M
Quarterly Burn
$105.3M
Runway
22.7 mo
Revenue
$119K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| elzovantinib | Phase 1 |
| oral repotrectinib | Phase 1/Phase 2 |
| tpx-0046 | Phase 1 |
| tpx-0131 | Phase 1 |
Frequently asked questions
How many drug candidates are in Turning Point Therapeutics, Inc.'s pipeline?
Turning Point Therapeutics, Inc. (TPTX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Turning Point Therapeutics, Inc.'s lead drug candidate?
Turning Point Therapeutics, Inc.'s most advanced tracked candidate is elzovantinib (Phase 1) for Advanced solid tumors harboring genetic alterations in MET.
What is Turning Point Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Turning Point Therapeutics, Inc. has approximately 22.7 months of cash runway.
Who is the CEO of Turning Point Therapeutics, Inc.?
San Diego is the chief executive officer of Turning Point Therapeutics, Inc. (TPTX).
Get the full picture on Turning Point Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.